## RECEIVE

## RAW SEQUENCE LISTING ERROR REPORT



The Biotechnology Systems Branch of the Scientific and Technical Information Center (STIC) detected errors when processing the following computer readable form:

Application Serial Number:	09/647,457B	
Source:	1600	
Date Processed by STIC:	4/2/103	1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1

THE ATTACHED PRINTOUT EXPLAINS DETECTED ERRORS.
PLEASE FORWARD THIS INFORMATION TO THE APPLICANT BY EITHER:

- i) INCLUDING A COPY OF THIS PRINTOUT IN YOUR NEXT COMMUNICATION TO THE APPLICANT, WITH A NOTICE TO COMPLY or,
- 2) TELEPHONING APPLICANT AND FAXING A COPY OF THIS PRINTOUT, WITH A NOTICE TO COMPLY

FOR CRF SUBMISSION QUESTIONS, PLEASE CONTACT MARK SPENCER, 703-308-4212.

FOR SEQUENCE RULES INTERPRETATION, PLEASE CONTACT ROBERT WAX, 703-308-4216.

PATENTIN ASSISTANCE: e-mail: robert.wax @ uspto.gov Telephone: 703-306-4119

TO REDUCE ERRORED SEQUENCE LISTINGS, PLEASE USE THE CHECKER VERSION 4.0 PROGRAM, ACCESSIBLE THROUGH THE U.S. PATENT AND TRADEMARK OFFICE WEBSITE. SEE BELOW FOR ADDRESS:

http://www.uspto.gov/web/offices/pac/checker

Applicants submitting genetic sequence information electronically on diskette or CD-Rom should be aware that there is a possibility that the disk/CD-Rom may have been affected by treatment given to all incoming mail.

Please consider using alternate methods of submission for the disk/CD-Rom or replacement disk/CD-Rom.

Any reply including a sequence listing in electronic form should NOT be sent to the 20231 zip code address for the United States Patent and Trademark Office, and instead should be sent via the following to the indicated addresses:

- 1. EFS-Bio (<http://www.uspto.gov/ebc/efs/downloads/documents.htm>, EFS Submission User Manual ePAVE)
- 2. U.S. Postal Service: U.S. Patent and Trademark Office, Box Sequence, P.O. Box 2327, Arlington, VA 22202 EFFECTIVE MAY 1, 2003 (via USPS): Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450
- 3. Hand Carry directly to:
  - U.S. Patent and Trademark Office, Technology Center 1600, Reception Area, 7<sup>th</sup> Floor, Examiner Name, Sequence Information, Crystal Mall One, 1911 South Clark Street, Arlington, VA 22202
  - U.S. Patent and Trademark Office, Box Sequence, Customer Window, Lobby, Room 1B03, Crystal Plaza Two, 2011 South Clark Place, Arlington, VA 22202
- 4. Federal Express, United Parcel Service, or other delivery service to: U.S. Patent and Trademark Office, Box Sequence, Room 1B03-Mailroom, Crystal Plaza Two, 2011 South Clark Place, Arlington, VA 22202

Revised 04/01/2003



1600

## Does Not Comply Corrected Diskette Needed

RAW SEQUENCE LISTING
PATENT APPLICATION: US/09/647,457B

DATE: 04/21/2003 TIME: 15:22:38

Input Set : A:\1276302.1.ST25.txt

Output Set: N:\CRF4\04212003\1647457B.raw

```
3 <110> APPLICANT: Yeda Research and Development Company Ltd.
      5 <120> TITLE OF INVENTION: ASSAY FOR THE DIAGNOSIS OF SCHIZOPHRENIA BASED ON A NEW
PEPTIDE
      7 <130> FILE REFERENCE: 1276302
      9 <140> CURRENT APPLICATION NUMBER: 09/647,457B
     10 <141> CURRENT FILING DATE: 2000-09-29
     12 <150> PRIOR APPLICATION NUMBER: PCT/IL99/00190
     13 <151> PRIOR FILING DATE: 1999-09-29
     15 <150> PRIOR APPLICATION NUMBER: 123925
     16 <151> PRIOR FILING DATE: 1998-04-02
     18 <160> NUMBER OF SEQ ID NOS: 15
     20 <170> SOFTWARE: PatentIn version 3.1
     22 <210> SEQ ID NO: 1
     23 <211> LENGTH: 17
     24 <212> TYPE: PRT
     25 <213> ORGANISM: Unknown
     27 <220> FEATURE:
     28 <223> OTHER INFORMATION: an isolated peptide which binds antibodies.
     30 <220> FEATURE:
     31 <221> NAME/KEY: MISC_FEATURE
     32 <222> LOCATION: (1)..(17)
     33 <223> OTHER INFORMATION: Xaa in position 1 may be (SGETEDTFIAD) (IAD)(AD), D or may be
absent;
     34
              Xaa in position 9 may be C, G, or P; Xaa in position 15 may be (AP)
     35
              , or (PA); Xaa in position 17 may be R, or may be absent.
     38 <400> SEQUENCE: 1
W--> 40 Xaa Leu Val Val Gly Leu Cys Thr Xaa Gln Ile Lys Thr Gly Xaa Cys
     41 1
    44 Xaa
     48 <210> SEQ ID NO: 2
     49 <211> LENGTH: 28
     50 <212> TYPE: PRT
    51 <213> ORGANISM: Unknown
     53 <220> FEATURE:
     54 <223> OTHER INFORMATION: being the immunologically active epitope
    56 <400> SEQUENCE: 2
    58 Ser Gly Glu Thr Glu Asp Thr Phe Ile Ala Asp Leu Val Val Gly Leu
                        5
                                             10
                                                                 15
    62 Cys Thr Gly Gln Ile Lys Thr Gly Ala Pro Cys Arg
                    20
    66 <210> SEQ ID NO: 3
    67 <211> LENGTH: 16
    68 <212> TYPE: PRT
```

69 <213> ORGANISM: Unknown

DATE: 04/21/2003

TIME: 15:22:38

```
Input Set : A:\1276302.1.ST25.txt
                      Output Set: N:\CRF4\04212003\I647457B.raw
      72 <223> OTHER INFORMATION: peptide capable of binding antibodies that are found in
 elevated
      73
               levels in body fluids of schizophrenic patients.
      75 <400> SEQUENCE: 3
      77 Leu Val Val Gly Leu Cys Thr Cys Gln Ile Lys Thr Gly Pro Ala Cys
      78 1
      81 <210> SEQ ID NO: 4
      82 <211> LENGTH: 20
      83 <212> TYPE: PRT
      84 <213> ORGANISM: Unknown
      86 <220> FEATURE:
     87 <223> OTHER INFORMATION: peptide capable of binding antibodies that are found in
elevated
     88
               levels in body fluids of schizophrenic patients.
      90 <400> SEQUENCE: 4
      92 Ile Ala Asp Leu Val Val Gly Leu Cys Thr Gly Gln Ile Lys Thr Gly
      93 1.
     96 Ala Pro Cys Arg
     97
                     20
     100 <210> SEQ ID NO: 5
     101 <211> LENGTH: 19
     102 <212> TYPE: PRT
     103 <213> ORGANISM: Unknown
     105 <220> FEATURE:
     106 <223> OTHER INFORMATION: peptide capable of binding antibodies that are found in
elevated
     107
               levels in body fluids of schizophrenic patients
     109 <400> SEQUENCE: 5
     111 Ala Asp Leu Val Val Gly Leu Cys Thr Gly Gln Ile Lys Thr Gly Ala
     112 1
                                              10
     115 Pro Cys Arg
     119 <210> SEQ ID NO: 6
     120 <211> LENGTH: 18
     121 <212> TYPE: PRT
     122 <213> ORGANISM: Unknown
     124 <220> FEATURE:
     125 <223> OTHER INFORMATION: peptide capable of binding antibodies that are found in
elevated
               levels in body fluids of schizophrenic patients
     128 <400> SEQUENCE: 6
     130 Asp Leu Val Val Gly Leu Cys Thr Gly Gln Ile Lys Thr Gly Ala Pro
     131 1
                                              10
     134 Cys Arg
     138 <210> SEQ ID NO: 7
     139 <211> LENGTH: 17
     140 <212> TYPE: PRT
     141 <213> ORGANISM: Unknown
     143 <220> FEATURE:
    144 <223> OTHER INFORMATION: peptide capable of binding antibodies that are found in
elevated
     145
               levels in body fluids of schizophrenic patients
     147 <400> SEQUENCE: 7
     149 Leu Val Val Gly Leu Cys Thr Gly Gln Ile Lys Thr Gly Ala Pro Cys
```

RAW SEQUENCE LISTING

PATENT APPLICATION: US/09/647,457B

DATE: 04/21/2003

TIME: 15:22:38

```
Input Set : A:\1276302.1.ST25.txt
                      Output Set: N:\CRF4\04212003\1647457B.raw
      153 Arg
      157 <210> SEQ ID NO: 8
      158 <211> LENGTH: 17
      159 <212> TYPE: PRT
      160 <213> ORGANISM: Unknown
      162 <220> FEATURE:
      163 <223> OTHER INFORMATION: peptide capable of binding antibodies that are found in
 elevated
                levels in body fluids of schizophrenic patients
      164
      166 <400> SEQUENCE: 8
      168 Leu Val Val Gly Leu Cys Thr Gly Gln Ile Lys Thr Gly Pro Ala Cys
      169 1
      172 Arg
      176 <210> SEQ ID NO: 9
      177 <211> LENGTH: 17
      178 <212> TYPE: PRT
      179 <213> ORGANISM: Unknown
      181 <220> FEATURE:
     182 <223> OTHER INFORMATION: peptide capable of binding antibodies that are found in
elevated ·
                levels in body fluids of schizophrenic patients
     183
      185 <400> SEQUENCE: 9
     187 Leu Val Val Gly Leu Cys Thr Pro Gln Ile Lys Thr Gly Pro Ala Cys
     188 1
     191 Arg
     195 <210> SEQ ID NO: 10
     196 <211> LENGTH: 20
     197 <212> TYPE: PRT
     198 <213> ORGANISM: Unknown
     200 <220> FEATURE:
     201 <223> OTHER INFORMATION: peptide capable of binding antibodies that are found in
elevated
     202
               levels in body fluids of schizophrenic patients
     204 <400> SEQUENCE: 10
     206 Ser Gly Glu Thr Glu Asp Thr Phe Ile Ala Asp Leu Val Val Gly Leu
     207 1
     210 Cys Thr Gly Gln
     211
     214 <210> SEQ ID NO: 11
     215 <211> LENGTH: 16
     216 <212> TYPE: PRT
     217 <213> ORGANISM: Unknown
     219 <220> FEATURE:
     220 <223> OTHER INFORMATION: peptide capable of binding antibodies that are found in
elevated
     221
               levels in body fluids of schizophrenic patients
     223 <400> SEQUENCE: 11
     225 Val Val Gly Leu Cys Thr Gly Gln Ile Lys Thr Gly Ala Pro Cys Arg
     226 1
                                              10
                                                                  15
     229 <210> SEQ ID NO: 12
     230 <211> LENGTH: 12
    231 <212> TYPE: PRT
    232 <213> ORGANISM: Unknown
```

RAW SEQUENCE LISTING

PATENT APPLICATION: US/09/647,457B

RAW SEQUENCE LISTING

PATENT APPLICATION: US/09/647,457B

DATE: 04/21/2003 TIME: 15:22:38

Input Set : A:\1276302.1.ST25.txt

Output Set: N:\CRF4\04212003\1647457B.raw

```
234 <220> FEATURE:
      235 <223> OTHER INFORMATION: peptide capable of binding antibodies that are found in
 elevated
                levels in body fluids of schizophrenic patients
      238 <400> SEQUENCE: 12
      240 Cys Thr Gly Gln Ile Lys Thr Gly Ala Pro Cys Arg
      241 1
      244 <210> SEQ ID NO: 13
      245 <211> LENGTH: 16
      246 <212> TYPE: PRT
      247 <213> ORGANISM: Unknown
      249 <220> FEATURE:
      250 <223> OTHER INFORMATION: peptide capable of binding antibodies that are found in
 elevated
                levels in body fluids of schizophrenic patients
      253 <400> SEQUENCE: 13
     255 Leu Val Val Gly Leu Cys Thr Gly Gln Ile Lys Thr Gly Ala Pro Cys
     256 1
                                              10
     259 <210> SEQ ID NO: 14
     260 <211> LENGTH: 15
     261 <212> TYPE: PRT
     262 <213> ORGANISM: Unknown
     264 <220> FEATURE:
     265 <223> OTHER INFORMATION: peptide capable of binding antibodies that are found in
elevated
     266
               levels in body fluids of schizophrenic patients
     268 <400> SEQUENCE: 14
     270 Leu Val Val Gly Leu Cys Thr Gly Gln Ile Lys Thr Gly Ala Pro
     271 1
                         5
     274 <210> SEQ ID NO: 15
     275 <211> LENGTH: 16
     276 <212> TYPE: PRT
     277 <213> ORGANISM: Unknown
     279 <220> FEATURE:
     280 <223> OTHER INFORMATION: peptide capable of binding antibodies that are found in
elevated
     281
               levels in body fluids of schizophrenic patients
```

285 Leu Val Val Gly Leu Cys Thr Gly Gln Ile Lys Thr Gly Pro Ala Cys

10

283 <400> SEQUENCE: 15

5

286 1

RAW SEQUENCE LISTING ERROR SUMMARY PATENT APPLICATION: US/09/647,457B

DATE: 04/21/2003 TIME: 15:22:39

Input Set : A:\1276302.1.ST25.txt

Output Set: N:\CRF4\04212003\I647457B.raw

## Please Note:

Use of n and/or Xaa have been detected in the Sequence Listing. Please review the Sequence Listing to ensure that a corresponding explanation is presented in the <220> to <223> fields of each sequence which presents at least one n or Xaa.

Seq#:1; Xaa Pos. 1,9,15,17

VERIFICATION SUMMARY

PATENT APPLICATION: US/09/647,457B

DATE: 04/21/2003 TIME: 15:22:39

Input Set : A:\1276302.1.ST25.txt

Output Set: N:\CRF4\04212003\1647457B.raw

L:40 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:1 after pos.:0 M:341 Repeated in SeqNo=1